{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:07:57Z","timestamp":1791122877389,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04827-z","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T01:33:04Z","timestamp":1760751184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Mirdametinib: FDA approved MEK inhibitor for neurofibromatosis type 1"],"prefix":"10.1007","volume":"95","author":[{"family":"Saara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Kamboj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4618-0177","authenticated-orcid":false,"given":"Dimpy","family":"Rani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"4827_CR1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/cancers13030463","volume":"13","author":"B Ozarslan","year":"2021","unstructured":"Ozarslan B, Russo T, Argenziano G, Santoro C, Piccolo V (2021) Cutaneous findings in neurofibromatosis type 1. Cancers 13:463. https:\/\/doi.org\/10.3390\/cancers13030463","journal-title":"Cancers"},{"key":"4827_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12916-023-02927-2","volume":"21","author":"X Hu","year":"2023","unstructured":"Hu X, Li W, Zeng K et al (2023) Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas. BMC Med 21:230. https:\/\/doi.org\/10.1186\/s12916-023-02927-2","journal-title":"BMC Med"},{"key":"4827_CR3","doi-asserted-by":"publisher","first-page":"100144","DOI":"10.1016\/j.hmedic.2024.100144","volume":"9","author":"A Jradi","year":"2025","unstructured":"Jradi A, Al Qassab M, Sleiman BEH, Karam K, El Hajj II, Fiani E (2025) An uncanny cause of abdominal pain: A case report of plexiform neurofibromatosis of the liver in a young patient with neurofibromatosis type 1. Med Rep 9:100144. https:\/\/doi.org\/10.1016\/j.hmedic.2024.100144","journal-title":"Med Rep"},{"key":"4827_CR4","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.3390\/cells9112365","volume":"9","author":"M Bergoug","year":"2020","unstructured":"Bergoug M, Doudeau M, Godin F, Mosrin C, Vall\u00e9e B, B\u00e9n\u00e9detti H (2020) Neurofibromin structure, functions and regulation. Cells 9:2365. https:\/\/doi.org\/10.3390\/cells9112365","journal-title":"Cells"},{"key":"4827_CR5","unstructured":"Grit JL (2021) Genetic and Epigenetic Regulation of Cell Signaling Guides the Clinical Progression of NF1-Related Neurofibromas. Dissertation, Van Andel Research Institute"},{"key":"4827_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/JCO.20.02220","volume":"39","author":"BD Weiss","year":"2021","unstructured":"Weiss BD, Wolters PL, Plotkin SR et al (2021) NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor Mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas. J Clin Oncol 39:797\u2013806. https:\/\/doi.org\/10.1200\/JCO.20.02220","journal-title":"J Clin Oncol"},{"key":"4827_CR7","doi-asserted-by":"publisher","unstructured":"Pellerino A, Verdijk RM, Nichelli L et al (2023) Diagnosis and treatment of peripheral and cranial nerve tumors with expert recommendations: an EUropean network for rare cancers (EURACAN) initiative. Cancers (Basel) 151930. https:\/\/doi.org\/10.3390\/cancers15071930","DOI":"10.3390\/cancers15071930"},{"key":"4827_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41698-021-00145-8","volume":"5","author":"S Nagabushan","year":"2021","unstructured":"Nagabushan S, Lau LM, Barahona P et al (2021) Efficacy of MEK Inhibition in a recurrent malignant peripheral nerve sheath tumor. NPJ Precis Oncol 5:9. https:\/\/doi.org\/10.1038\/s41698-021-00145-8","journal-title":"NPJ Precis Oncol"},{"key":"4827_CR9","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1136\/jmedgenet-2021-108301","volume":"59","author":"B Garcia","year":"2022","unstructured":"Garcia B, Catasus N, Ros A et al (2022) Neurofibromatosis type 1 families with first-degree relatives harbouring distinct NF1 pathogenic variants. Genetic counselling and Familial diagnosis: what should be offered? J Med Genet 59:1017\u20131023. https:\/\/doi.org\/10.1136\/jmedgenet-2021-108301","journal-title":"J Med Genet"},{"key":"4827_CR10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jpsychires.2022.07.035","volume":"154","author":"A Del Castillo","year":"2022","unstructured":"Del Castillo A, Dekarchuk M, Inker T, Hussey M, Walsh KS (2022) Understanding the neurofibromatosis type 1 (NF1) experience and the priorities of individuals with NF1 and their caregivers for cognitive and social-emotional research. J Psychiatr Res 154:268\u2013277. https:\/\/doi.org\/10.1016\/j.jpsychires.2022.07.035","journal-title":"J Psychiatr Res"},{"key":"4827_CR11","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.3390\/cancers13153880","volume":"13","author":"O Rabab\u2019h","year":"2021","unstructured":"Rabab\u2019h O, Gharaibeh A, Al-Ramadan A, Ismail M, Shah J (2021) Pharmacological approaches in neurofibromatosis type 1-associated nervous system tumors. Cancers 13:3880. https:\/\/doi.org\/10.3390\/cancers13153880","journal-title":"Cancers"},{"key":"4827_CR12","doi-asserted-by":"publisher","first-page":"dmm049362","DOI":"10.1242\/dmm.049362","volume":"15","author":"C Anastasaki","year":"2022","unstructured":"Anastasaki C, Orozco P, Gutmann DH (2022) RAS and beyond: the many faces of the neurofibromatosis type 1 protein. Dis Model Mech 15:dmm049362. https:\/\/doi.org\/10.1242\/dmm.049362","journal-title":"Dis Model Mech"},{"key":"4827_CR13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s12935-020-01570-8","volume":"20","author":"J Tao","year":"2020","unstructured":"Tao J, Sun D, Dong L, Zhu H, Hou H (2020) Advancement in research and therapy of NF1 mutant malignant tumors. Cancer Cell Int 20:492. https:\/\/doi.org\/10.1186\/s12935-020-01570-8","journal-title":"Cancer Cell Int"},{"key":"4827_CR14","unstructured":"National Institute of Neurological Disorders and Stroke (n.d.), Neurofibromatosis U.S. Department of Health and Human Services. https:\/\/www.ninds.nih.gov\/health-information\/disorders\/neurofibromatosis. Accessed 28 Sept 2025"},{"key":"4827_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/PHMT.S362679","volume":"14","author":"HB Radtke","year":"2023","unstructured":"Radtke HB, Berger A, Skelton T, Goetsch Weisman A (2023) Neurofibromatosis type 1 (NF1): addressing the transition from pediatric to adult care. Pediatr Health Med Ther 14:19\u201332. https:\/\/doi.org\/10.2147\/PHMT.S362679","journal-title":"Pediatr Health Med Ther"},{"key":"4827_CR16","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.2340\/actadv.v103.5758","volume":"103","author":"NASI Lamprini","year":"2023","unstructured":"Lamprini NASI, Alexopoulos A, Kokkinou E et al (2023) Characteristics of Caf\u00e9-au-lait macules and their association with the neurofibromatosis type I genotype in a cohort of Greek children. Acta Derm Venereol 103:5758. https:\/\/doi.org\/10.2340\/actadv.v103.5758","journal-title":"Acta Derm Venereol"},{"key":"4827_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1167\/tvst.11.2.10","volume":"11","author":"MF Pimentel","year":"2022","unstructured":"Pimentel MF, Heath A, Wan MJ et al (2022) Prevalence of choroidal abnormalities and Lisch nodules in children meeting clinical and molecular diagnosis of neurofibromatosis type 1. Transl Vis Sci Technol 11:10. https:\/\/doi.org\/10.1167\/tvst.11.2.10","journal-title":"Transl Vis Sci Technol"},{"key":"4827_CR18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/jcm14020451","volume":"14","author":"A Nastac","year":"2025","unstructured":"Nastac A, Panaitescu AM, Hulu\u021b\u0103 I et al (2025) Maternal and fetal complications in pregnant women with neurofibromatosis type 1: literature review and two case reports. J Clin Med 14:451. https:\/\/doi.org\/10.3390\/jcm14020451","journal-title":"J Clin Med"},{"key":"4827_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12885-023-10996-y","volume":"23","author":"AE Armstrong","year":"2023","unstructured":"Armstrong AE, Belzberg AJ, Crawford JR, Hirbe AC, Wang ZJ (2023) Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. BMC Cancer 23:553. https:\/\/doi.org\/10.1186\/s12885-023-10996-y","journal-title":"BMC Cancer"},{"key":"4827_CR20","unstructured":"SpringWorks Therapeutics I (2025) GOMEKLI\u2122 (mirdametinib) [Package insert]. Stamford, CT: SpringWorks Therapeutics, Inc. https:\/\/www.springworkstx.com\/gomekli. Accessed 28 Sept 2025"},{"key":"4827_CR21","unstructured":"National Cancer Institute (2025) Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA v28.0). U.S. Department of Health and Human Services. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events Accessed 26 Sept 2025"},{"key":"4827_CR22","unstructured":"National Cancer Institute (n d.) Mirdametinib available agents, NCI Formulary. https:\/\/nciformulary.cancer.gov\/available_agents\/mirdametinib. Accessed 28 Sept 2025"},{"key":"4827_CR23","unstructured":"RxList (n.d.) Gomekli (Mirdametinib Capsules and Tablets): Side effects, uses, dosage, interactions, warnings. https:\/\/www.rxlist.com\/gomekli-drug.htm. Accessed 28 Sept 2025"},{"key":"4827_CR24","unstructured":"World Intellectual Property Organization (2023) Solid state forms of Mirdametinib and process for Preparation thereof. WO2023223205A1. https:\/\/patents.google.com\/patent\/WO2023223205A1. Accessed 28 Sept 2025"},{"key":"4827_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40265-024-02117-1","volume":"85","author":"SM Hoy","year":"2025","unstructured":"Hoy SM (2025) Mirdametinib: first approval. Drugs 85:1\u20138","journal-title":"Drugs"},{"key":"4827_CR26","unstructured":"MedlinePlus (n.d.) Mirdametinib. U.S. National Library of Medicine. https:\/\/medlineplus.gov\/druginfo\/meds\/a622043.html. Accessed 28 Sept 2025"},{"key":"4827_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI60578","volume":"123","author":"WJ Jessen","year":"2013","unstructured":"Jessen WJ, Miller SJ, Jousma E et al (2013) MEK Inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 123:340\u2013347. https:\/\/doi.org\/10.1172\/JCI60578","journal-title":"J Clin Invest"},{"key":"4827_CR28","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/pbc.25546","volume":"62","author":"E Jousma","year":"2015","unstructured":"Jousma E, Rizvi TA, Wu J et al (2015) Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1. Pediatr Blood Cancer 62:1709\u20131716. https:\/\/doi.org\/10.1002\/pbc.25546","journal-title":"Pediatr Blood Cancer"},{"key":"4827_CR29","unstructured":"ClinicalTrials.gov (2023) Mirdametinib monotherapy in adults with neurofibromatosis 1 (NF1) and cutaneous neurofibromas (cNF). ClinicalTrials.gov Identifier: NCT06159166. https:\/\/clinicaltrials.gov\/study\/NCT06159166. Accessed 29 Sept 2025"},{"key":"4827_CR30","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1200\/JCO.24.01034","volume":"43","author":"CL Moertel","year":"2025","unstructured":"Moertel CL, Hirbe AC, Shuhaiber HH et al (2025) ReNeu: A pivotal, phase IIb trial of Mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. J Clin Oncol 43:716\u2013729. https:\/\/doi.org\/10.1200\/JCO.24.01034","journal-title":"J Clin Oncol"},{"key":"4827_CR31","unstructured":"RxList (2025) Mirdametinib: Side Effects, Uses, Dosage, Interactions, Warnings. RxList. Mirdametinib: Side Effects, Uses, Dosage, Interactions, Warnings. Accessed 29 Sept 2025"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04827-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04827-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04827-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T14:03:24Z","timestamp":1760796204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04827-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4827"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04827-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}}],"article-number":"101"}}